Sweden · Delayed Price · Currency is SEK Bactiguard Holding AB Company Description
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas.
It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded.
The company also has a portfolio of wound management products, such as Hydrocyn Aqua, an antimicrobial solution and gel for improved wound healing; and surgical sutures comprising non-absorbable, natural absorbable, synthetic absorable, and specialty sutures.
It operates in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally.
The company has licensed partnership with Becton, Dickinson & Company for urinary catheter bardex IC and lubrisil IC; Well Lead Medical for catheters and tubes; and Zimmer Biomet for orthopedic trauma implants.
The company was founded in 2005 and is headquartered in Stockholm, Sweden.
| Country | Sweden |
| Founded | 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 177 |
| CEO | Christine Lind |
Contact Details
Address: Vasagatan 11 Stockholm, 111 20 Sweden | |
| Phone | 46 84 40 58 80 |
| Website | bactiguard.com |
Stock Details
| Ticker Symbol | BACTI.B |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0005878741 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Christine Lind | Chief Executive Officer |
| Patrick Fruergaard Bach | Chief Financial Officer |
| Dr. Nathaniel Bachrach Ph.D. | Chief Scientific Officer |
| Nina Nornholm | Executive Vice President of Communications and Investor Relations |
| Kajsa Björklund | Executive Vice President of Research and Development |